Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pain Therapeutics, Inc.    PTIE

Delayed Quote. Delayed  - 01/13 10:00:00 pm
0.6003 USD   +3.50%
01/10 DEADLINE UPCOMI : PTIE) Investor Lawsuit
2016 PAIN THERAPEUTI : to Discuss REMOXY ER with FDA
2016 Pain Therapeutics to Discuss REMOXY® ER with FDA
News SummaryMost relevantAll newsSector newsTweets 

Pain Therapeutics, Inc. : Pain Therapeutics Reports 2012 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2013 | 04:27pm CET

Pain Therapeutics Reports 2012 Financial Results Innovation, Disciplined Spending Expected in 2013

AUSTIN, Texas, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the full year ended December 31, 2012. Net loss was $3.4 million in 2012, or $0.08 per share, compared to a net loss of $2.6 million in 2011, or $0.06 per share.

"We are excited by the prospect of having important regulatory readouts on REMOXY® in 2013," said Remi Barbier, Chairman, President & CEO. "In the interim, we'll maintain our existing corporate strategy to spend modestly and to keep innovation at the top of our agenda."

At December 31, 2012, cash and equivalents were $56.3 million. The Company has no debt. Management expects net cash usage for the first half of 2013 to be under $5.0 million. 

2012 Financial Detail

  • In December 2012, Pain Therapeutics completed a special nondividend distribution to shareholders totaling $34.0 million, or $0.75 per share.
  • Revenue decreased to $10.9 million in 2012 from $11.5 million in 2011, primarily due to lower collaboration revenue from reimbursements of research and development expenses under our collaboration agreement with Pfizer, Inc. (NYSE:PFE).
  • Research and development expenses decreased to $7.6 million in 2012 from $8.3 million in 2011, primarily due to lower headcount and facilities-related costs. Research and development expenses included $3.2 million in non-cash stock related compensation costs in 2012 (including $0.8 million related to the nondividend distribution in December 2012) and $2.7 million in 2011. 
  • General and administrative expenses increased to $7.2 million in 2012 from $6.7 million in 2011, primarily due to higher non-cash stock related compensation costs, offset in part by lower headcount and facilities-related costs. General and administrative expenses included $3.4 million in non-cash stock related compensation costs in 2012 (including $1.0 million related to the nondividend distribution in December 2012) and $2.8 million in 2011. 


Our lead drug candidate is called REMOXY (oxycodone) Extended-Release Capsules CII. REMOXY is an investigational drug with a unique, controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain. REMOXY is designed to discourage common methods of tampering associated with prescription analgesic misuse and abuse.

  • Pfizer is our exclusive, worldwide commercial partner for REMOXY and three other abuse-resistant prescription pain medications (except in Australia/New Zealand).
  • REMOXY received a Complete Response Letter in December 2008 and in June 2011. Pfizer has sole responsibility for addressing the concerns described in the FDA's Complete Response Letter, at its own expense. 

REMOXY Deal Economics

  • To date, we have received total cash payments of $185.0 million in program fees and milestone payments under our strategic alliance with Pfizer in connection with the development of REMOXY and three other abuse-resistant drug candidates.
  •  We are also eligible to receive up to an additional $120.0 million in clinical/regulatory milestone payments, including a $15.0 million payment upon FDA approval of REMOXY.
  • Upon the commercial launch of REMOXY, we will receive from Pfizer a royalty of 20% of net sales in the United States, except as to the first $1.0 billion in cumulative net sales, which royalty is set at 15%. Outside the United States, the royalty rate is 10%.
  • We will also receive from Pfizer a supplemental royalty fee payment of 6.0% to 11.5% of net sales, depending on the range of total dollar sales in each year. This supplemental payment is equal to the full amount of our financial obligations to Durect Corporation (Nasdaq:DRRX), our exclusive supplier of certain excipients in REMOXY.
  • Our development expenses for REMOXY and three other abuse-resistant pain medications that are in various stages of development, including hydrocodone, hydromorphone and oxymorphone, are reimbursed by Pfizer.
  • Pain Therapeutics retains commercial rights to REMOXY and three other abuse-resistant drug candidates in Australia/New Zealand. We have not yet announced a market entry strategy for these territories.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit www.paintrials.com.

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to potential regulatory readouts or other regulatory feedback regarding REMOXY development; the company's projected cash requirements for the first half of 2013; potential future milestone payments and royalties based on revenue from REMOXY; the potential development of other abuse-resistant drug candidates; and funding obligations of Pfizer. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in obtaining regulatory approval of REMOXY and in development, testing and pursuit of regulatory approval of our other drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates; difficulties or delays in commercialization efforts with respect to our products, if any are approved for marketing, or failure of such products to gain market acceptance; the uncertainty of patent protection for our intellectual property or trade secrets; unanticipated additional research and development, litigation and other costs; the timing and receipt of funds from Pfizer; potential diversion of resources from the pursuit of development and commercialization of drug candidates subject to our strategic alliance with Pfizer; and the potential for abuse-resistant pain medications or other competing products or therapies to be developed by competitors and potential competitors or others. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.

(in thousands, except per share amounts)
Three Months Ended December 31, Year Ended December 31,
2012 2011 2012 2011(1)
Program fee revenue   $ 2,468  $ 2,724  $ 10,641  $ 10,897
Collaboration revenue   --   23  249  587
Total revenue   2,468  2,747  10,890  11,484
Operating expenses 
Research and development   2,101  1,711  7,605  8,300
General and administrative   2,209  1,620  7,182  6,698
Total operating expenses   4,310  3,331  14,787  14,998
Operating loss   (1,842)  (584)  (3,897)  (3,514)
Interest income   46  193  451  901
Net loss   $ (1,796)  $ (391)  $ (3,446)  $ (2,613)
Net loss per share - basic and diluted   $ (0.04)  $ (0.01)  $ (0.08)  $ (0.06)
Weighted-average shares used in computing net loss per share - basic and diluted   44,903  44,671  44,753  44,160
December 31,
2012 2011(1)
Current assets 
Cash, cash equivalents and marketable securities   $ 56,254  $ 98,131
Other current assets   253  358
Total current assets   56,507  98,489
Non-current assets 
Property and equipment, net   --   122
Other assets   352  352
Total assets   $ 56,859  $ 98,963
Liabilities and stockholders' equity 
Current liabilities 
Accounts payable and accrued development expenses   $ 1,290  $ 1,378
Deferred program fee revenue - current portion   7,832  10,897
Other accrued liabilities   877  997
Total current liabilities   9,999  13,272
Non-current liabilities 
Deferred program fee revenue - non-current portion   33,287  40,863
Other liabilities   437  435
Total liabilities   43,723  54,570
Stockholders' equity 
Common stock   45  45
Additional paid-in-capital   148,738  176,425
Accumulated other comprehensive income   4  128
Accumulated deficit   (135,651)  (132,205)
Total stockholders' equity   13,136  44,393
Total liabilities and stockholders' equity   $ 56,859  $ 98,963
(1) Derived from the Company's annual financial statements as of December 31, 2011, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.
CONTACT: Peter S. Roddy

         Vice President and Chief Financial Officer

         Pain Therapeutics, Inc.


         (512) 501-2450
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
01/10 DEADLINE UPCOMING IN $8.5 MILLION SE : PTIE) Investor Lawsuit
2016 Pain Therapeutics to Discuss REMOXY® ER with FDA
2016 PAIN THERAPEUTICS : Research Reports Initiation on Biotech Stocks -- Pacific Bio..
2016 PAIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Other Events..
2016 PAIN THERAPEUTICS INC : Notice of Delisting or Failure to Satisfy a Continued Li..
2016 PAIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
2016 PAIN THERAPEUTICS : reports 3Q loss
2016 PAIN THERAPEUTICS INC : Results of Operations and Financial Condition (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Pain Therapeutics net loss improves in Q3
2016 Pain Therapeutics beats by $0.01
2016 BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..
2016 Midday Gainers / Losers
Financials ($)
Sales 2016 -
EBIT 2016 -20,2 M
Net income 2016 -17,2 M
Debt 2016 11 000 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 0
EV / Sales 2017 5 606x
Capitalization 27,7 M
More Financials
Duration : Period :
Pain Therapeutics, Inc. Technical Analysis Chart | PTIE | US69562K1007 | 4-Traders
Full-screen chart
Technical analysis trends PAIN THERAPEUTICS...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 1,75 $
Spread / Average Target 192%
Consensus details
EPS Revisions
More Estimates Revisions
Remi Barbier Chairman, President & Chief Executive Officer
Nadav Friedmann COO, Class I Director & Chief Medical Officer
Peter S. Roddy Chief Financial Officer & Vice President
Robert Z. Gussin Independent Class II Director
Sanford R. Robertson Independent Class III Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.6.78%116 141
ACTELION LTD4.90%24 663
More Results